Fuertes, Baby Boy .
HRN: 22-13-86 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/30/2022
AMPICILLIN 250MG (VIAL)
10/30/2022
11/03/2022
IV
170mg
Q12
Maternal Factors: (+) RAgT; Thinly MSAF
Waiting Final Action
Indication: Prophylaxis Type of Infection: Prophylaxis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes